References
- Adams J, Palombella V J, Sausville E A, Johnson J, Destree A, Lazarus D D, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615–2622
- Grogan T M, Van Camp B, Kyle R A, Müller-Hermelink H K, Harris N L. Plasma cell neoplasms. WHO Classification of Tumours, Pathology & Genetics – Tumours of Haematopoietic and Lymphoid Tissues, E S Jaffe, N L Harris, H Stein, J W Vardinman. IARC Press, Lyon 2001; 142
- Bladé J, Kyle R A. Non-secretory myeloma, immunoglobulin D myeloma, and plasma cell leukaemia. Hematol Oncol Clin of North Am 1999; 13: 1259–1272
- Drake M, Morris C, Hagman A, Lopponen T, Bjorkstrand B, Gahrton G, et al. Outcome after autologous transplantation in primary plasma cell leukaemia. Bone Marrow Transplant 2004; 33: 112
- Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123
- Bradwell A R, Carr-Smith H D, Mead G P, Tang L X, Showell P J, Drayson M T, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673–680
- Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Bortezomib or high-dose Dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
- Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson P G, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172
- Esparis-Ogando A, Alegre A, Aguado B, Mateo G, Gutierrez N, Blade J, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005; 114: 665–667
- Hideshima T, Richardson P, Chauhan D, Palombella V J, Elliott P J, Adams J, Anderson K C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–3076
- Ma M H, Yang H H, Parker K, Manyak S, Friedman J M, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. J Clin Cancer Res 2003; 9: 1136–1144
- Mitsiades N, Mitsiades C S, Richardson P G, Poulaki V, Tai Y T, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380
- Oakervee H E, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755–762
- Perez-Simon J A, Garcia-Sanz R, Tabernero M D, Almeida J, Gonzalez M, Fernandez-Calvo J, et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood 1998; 91: 3366–3371
- Greipp P R, San Miguel J, Durie B G, Crowley J J, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420